rais estim follow result maintain
equal-weight rate given uncertainti baricitinib
fda action june assum mg approv
black box warn competitor novo oral sema
rais revenue ep rais revenue
respect rais ep
respect follow beat rais revenu guidanc
ep guidanc driven mix factor lower
estimate rebates/discount us lower medicaid util favor payer
mix sever product fx slightli lower tax rate
rais revenue despit significantli lower bari bump revenue
ep upsid exist franchis
off-set reduct us baricitinib revenue
total also cut us bari total
project consist management guidanc revenue
bottom end management target impli base upon
compound-annual-growth-rate revenue oper margin
consist manag oper margin goal least
baricitinib fda action june difficult predict current assumpt
fda approv baricitinib black box warn dvt/pe
risk downsid would fda reject mg dose
upsid would fda approv mg dose black box super-bul
upsid would fda approv mg dose black box
potenti competitor oral sema newsflow watch expect top-line result
pioneer vs jardianc pioneer vs januvia
pioneer flexibl dose vs januvia end novo oral sema
data detail june ada could elucid drug side effect profil
recal seen sema posit result pioneer vs placebo thu
far novo cover vincent meunier
baricitinib jak fda action rheumatoid arthriti june
competitor novo oral semaglutid phase trial result
implic long-term trulic prospect
major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
elanco anim health financi strateg updat relat exit
decis call late juli
galcanezumab cgrp pdufa migrain prevent oct estimate
pt base case ep premium peer mean due
lilli better growth prospect ep compound-annual-growth-rate vs group average off-set
uncertainti around next key event novo oral sema ph bari fda action
see solid growth prospect balanc premium valuat
risk achiev price target
upsid risk posit financi result project new product revenu
disappoint compel extern strateg action
downsid risk neg fda action bari compet drug surpris upsid
financi result fall short expect face us price pressur pipelin
